Upadacitinib blocks Janus kinases, the enzymes that carry signals from inflammatory cytokine receptors into the cell nucleus. It is more selective for JAK1 than tofacitinib, which was designed to reduce off-target effects. It is licensed across an unusually wide range of conditions - rheumatoid and psoriatic arthritis, axial spondyloarthritis, atopic eczema, ulcerative colitis and Crohn's disease - and it is a tablet rather than an injection. The class safety restrictions apply to it in full.
Follow the plan your specialist gave you. This guide contains no doses.
The class restrictions
A large safety trial of tofacitinib found higher rates of major cardiovascular events, cancers, blood clots, serious infections and death compared with TNF inhibitors.
Regulators extrapolated that finding to the whole JAK inhibitor class, including upadacitinib, since the data was not available for each drug individually.
JAK inhibitors should therefore be used only if no suitable alternative exists in people who:
- Are aged 65 or over
- Are current or long-term former smokers
- Have cardiovascular risk factors
- Have risk factors for cancer
Caution also applies with risk factors for blood clots - previous clot, major surgery, immobility, combined hormonal contraception or HRT.
Whether greater JAK1 selectivity translates into genuinely lower risk is an open question and an active area of study. Current advice treats the class together.
See tofacitinib.
If you fall into one of those groups and are taking upadacitinib, that is not a reason to stop unilaterally - it is a reason to have the conversation at your next review.
Why it is used anyway
For eczema in particular, JAK inhibitors work fast - itch frequently improves within days, which is quicker than any biologic.
For someone in severe distress from itch, that speed matters.
Being a tablet, it also suits people who cannot manage injections, and it can be stopped quickly if a problem develops - which an injected antibody with a long half-life cannot.
For eczema the alternative is dupilumab, which is slower but avoids the monitoring and the class restrictions entirely - see dupilumab.
Shingles
JAK inhibitors carry a notably increased risk of herpes zoster, higher than with biologics, and upadacitinib's rate is at the upper end of the class.
Vaccination against shingles should be considered before starting, using the non-live vaccine, which is suitable for people who are immunosuppressed.
Report a painful blistering rash promptly - antiviral treatment works best started within 72 hours. See valaciclovir.
Screening before starting
Tuberculosis screening is required - history, chest X-ray and an interferon gamma release assay - along with hepatitis B and C serology.
Blood counts, liver function and lipids are checked at baseline.
Monitoring during treatment
Lipids rise on JAK inhibitors, typically within the first weeks, and are checked a couple of months after starting. A statin is frequently added - see pravastatin.
Lymphocyte, neutrophil and haemoglobin counts are monitored, and treatment is interrupted if they fall below thresholds.
Liver function is checked periodically, and creatine kinase can rise.
See monitoring long-term medicines.
Infection
Serious infections are more common, and the usual signs can be blunted.
Seek medical advice promptly for fever, persistent sore throat, a cough that will not settle, burning on passing urine, or a wound that is not healing.
Treatment is paused during a significant infection and restarted once it has resolved.
Live vaccines are avoided. Inactivated vaccines are recommended.
Carry your alert card - see infection risk on immune-suppressing medicines.
Blood clots
Seek urgent help for pain, swelling or redness in a calf, or sudden breathlessness, chest pain or coughing blood.
Tell your prescriber about any previous clot, and about hormonal contraception or HRT.
Acne
Acne is a surprisingly common side effect of upadacitinib, particularly in the eczema population, appearing in the first weeks.
It is usually mild and manageable with standard treatment - see tretinoin.
Interactions
Upadacitinib is cleared mainly by CYP3A4. Strong inhibitors including clarithromycin and some antifungals raise levels, and the dose may be reduced.
Strong inducers such as rifampicin and carbamazepine reduce effectiveness.
See clarithromycin.
It is not combined with biologics or with potent immunosuppressants such as azathioprine and ciclosporin.
Where it fits
Upadacitinib is generally used after conventional treatments have failed - methotrexate in rheumatoid arthritis, topical treatment and often a biologic in eczema, and standard therapy in bowel disease.
Its breadth of licence means one drug can sometimes cover two conditions occurring together, which is a genuine advantage where someone has both arthritis and colitis. See methotrexate.
Taking it
Once daily, with or without food. Tablets are modified-release and must be swallowed whole, never crushed or split.
See cutting and crushing tablets.
It is not used in pregnancy, and effective contraception is advised during treatment and for a period afterwards.
If this was useful, Secukinumab: Blocking Interleukin-17 is worth reading next, and Conditions collects the rest.